Fusion Pharmaceuticals Inc. (FUSN)

21.25 +0.01 (+0.05%) At close: 04:00PM EDT

Fusion Pharmaceuticals Inc.

270 Longwood Road South
Hamilton, ON L8P 0A6
Canada
289 799 0891
https://www.fusionpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 101

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. John F. Valliant Ph.D.	Founder, CEO & Director	911.34k	N/A	1971
Dr. Christopher Paul Leamon Ph.D.	Chief Scientific Officer	N/A	N/A	1966
Ms. Amanda Cray	Senior Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Maria D. Stahl	Chief Legal Officer	N/A	N/A	1971
Mr. Eric S. Hoffman Ph.D.	Senior Vice President of Business Development	N/A	N/A	1970
Dr. Cara Ferreira Ph.D.	Chief of Staff	N/A	N/A	N/A
Dr. Joanne Schindler	Executive Vice President of Medical Director & Clinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Corporate Governance

Fusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.